These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 28819882)

  • 21. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma.
    Isazadeh A; Hajazimian S; Garshasbi H; Shadman B; Baghbanzadeh A; Chavoshi R; Taefehshokr S; Farhoudi Sefidan Jadid M; Hajiasgharzadeh K; Baradaran B
    J Cell Physiol; 2021 Feb; 236(2):791-805. PubMed ID: 32592235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune checkpoint inhibitors in multiple myeloma: A review of the literature.
    Caserta S; Innao V; Musolino C; Allegra A
    Pathol Res Pract; 2020 Oct; 216(10):153114. PubMed ID: 32853951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy for multiple myeloma: Current status and future directions.
    Ayed AO; Chang LJ; Moreb JS
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):399-412. PubMed ID: 26153389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging immune targets for the treatment of multiple myeloma.
    Sohail A; Mushtaq A; Iftikhar A; Warraich Z; Kurtin SE; Tenneti P; McBride A; Anwer F
    Immunotherapy; 2018 Feb; 10(4):265-282. PubMed ID: 29421983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting B-cell maturation antigen in multiple myeloma.
    Tai YT; Anderson KC
    Immunotherapy; 2015; 7(11):1187-99. PubMed ID: 26370838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel immunotherapies.
    Yi Q
    Cancer J; 2009; 15(6):502-10. PubMed ID: 20010170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
    van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
    Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [CD38 antibodies in multiple myeloma].
    Moreaux J
    Med Sci (Paris); 2019 Dec; 35(12):1001-1004. PubMed ID: 31903907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
    D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F
    Curr Med Chem; 2019; 26(32):5968-5981. PubMed ID: 29756564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
    van de Donk NWCJ; Usmani SZ
    Front Immunol; 2018; 9():2134. PubMed ID: 30294326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.
    De Luca F; Allegra A; Di Chio C; Previti S; Zappalà M; Ettari R
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune therapy in multiple myeloma.
    Luptakova K; Avigan D
    Clin Adv Hematol Oncol; 2015 Nov; 13(11):767-75. PubMed ID: 27058703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel immunotherapies in multiple myeloma.
    Ohmine K; Uchibori R
    Int J Hematol; 2022 Jun; 115(6):799-810. PubMed ID: 35583724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seeking Convergence and Cure with New Myeloma Therapies.
    Choudhry P; Galligan D; Wiita AP
    Trends Cancer; 2018 Aug; 4(8):567-582. PubMed ID: 30064664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-based therapies in the management of multiple myeloma.
    Zanwar S; Nandakumar B; Kumar S
    Blood Cancer J; 2020 Aug; 10(8):84. PubMed ID: 32829378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
    D'Agostino M; Raje N
    Leukemia; 2020 Jan; 34(1):21-34. PubMed ID: 31780814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
    Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
    Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
    [No Abstract]   [Full Text] [Related]  

  • 39. The challenges of checkpoint inhibition in the treatment of multiple myeloma.
    Paul B; Kang S; Zheng Z; Kang Y
    Cell Immunol; 2018 Dec; 334():87-98. PubMed ID: 30342750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy in multiple myeloma: when, where, and for who?
    Verkleij CPM; Korst CLBM; van de Donk NWCJ
    Curr Opin Oncol; 2020 Nov; 32(6):664-671. PubMed ID: 32852308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.